📌 Recap of the Original Analysis
Back in June 2025, we published our deep-dive on Intellia Therapeutics (NASDAQ: NTLA). At that time, NTLA was deeply oversold near $8, with RSI bottoming and MACD turning upward. Institutional ownership stood near 89%, with heavy inflows from ARK, Vanguard, and State Street.
We structured a LEAPS strategy using the Jan 15, 2027 $5 call, priced at $5.25 per contract. With each contract controlling 100 shares, that meant an initial cost of $525.
📎 Link to the Original NTLA Analysis Article
Our thesis called for:
- Near-term bounce to $11.50
- Intermediate rally to $14–15
- Catalyst-driven move to $20–22
- Stretch upside above $30 with trial momentum
The breakeven stock price was $10.25, giving us a wide margin of safety on the trade.
📊 What Happened Next
Fast forward to late September 2025, and NTLA has more than doubled off its summer lows, closing at $16.92. The Jan 2027 $5 LEAPS call we targeted has surged to $12.65.
💰 Profit Breakdown
This is where the numbers really matter:
- Entry Premium Paid: $5.25 per contract ($525 total)
- Exit Premium Received: $12.65 per contract ($1,265 total)
- Net Profit per Contract: $740
- Return on Investment: +141%
For example:
- Buying 1 contract = +$740 profit
- Buying 5 contracts = +$3,700 profit
- Buying 10 contracts = +$7,400 profit
This all happened in less than four months — a textbook demonstration of why LEAPS calls on deeply oversold, catalyst-rich biotech names can deliver outsized returns when executed with discipline.
📈 How the Strategy Played Out
- Stock Recovery: NTLA rebounded sharply from $8 to nearly $17, validating the entry thesis of a bounce from oversold levels.
- Technical Alignment: RSI rose from sub-30 to near 70, and MACD momentum flipped positive, providing confirmation of trend reversal.
- Options Leverage: Delta on the $5 LEAPS call was already high (0.88 at entry), which allowed the position to behave almost like stock ownership — but with amplified percentage gains.
- Profit Target Execution: With the stock moving through $14–15, the second target zone was reached, and we booked profits into strength.
No need to wait for clinical readouts or trial catalysts — the trade achieved its goals well ahead of schedule.
🧠 Why This Matters
This NTLA trade highlights three critical principles of successful options investing:
- Defined Risk: Maximum loss was capped at $525 per contract.
- Leverage Without Gambling: High-delta LEAPS provided equity-like exposure but multiplied percentage gains.
- Profit Discipline: By taking profits as the plan dictated, we avoided the common trap of holding too long.
The end result was a +141% return, realized and secured.
🔑 Key Takeaway for Readers
This article is not about predicting the future of NTLA. It’s about showing the power of a disciplined strategy: identifying a setup, structuring a trade, defining risk, and executing profit-taking at the right levels.
If you followed this trade from the beginning, you’ve already booked triple-digit percentage returns. That’s what this update is truly about — demonstrating how sticking to the plan produces real, tangible results.
📢 Don’t Miss the Next Opportunity
Trades like NTLA don’t happen every day, but when they do, preparation and discipline make all the difference. Don’t miss out on the next big move. Check out one of our latest stock options analyses here:
⚠️ Disclaimer
This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Options trading carries substantial risk, including the potential loss of your entire investment. Past performance is not indicative of future results. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions.
✅ Final Word:
The NTLA Jan 2027 $5 LEAPS call turned $525 into $1,265 in under four months — a +141% profit. This was not luck, but the result of following a structured plan from start to finish.
